| Page 41 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Bone Marrow Transplant Recipients During Childhood at Increased Risk for Severe Chronic Health Conditions

Patients who underwent allogeneic bone marrow transplantation (BMT) as children were at increased risk for severe or life-threatening chronic health conditions. These findings were presented during the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition.

Existing agents, novel agents, or transplantation for high-risk MDS

Author(s): 
Bart L Scott
Primary Author: 
Scott BL
Journal Title: 
Hematology. American Society of Hematology. Education Program
Original Publication Date: 
Dec 2020

The decision algorithm for treatment of advanced myelodysplastic syndrome (MDS) (intermediate- to very high-risk by the revised International Prognostic Scoring System [IPSS-R]) is complex.

Bone Marrow Disease(s): 

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Author(s): 
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE
Primary Author: 
Oran B
Journal Title: 
Blood Advances
Original Publication Date: 
Nov 2020

This study investigated the efficacy and safety of azacitidine maintenance in the posttransplant setting based on the encouraging phase 1/2 reports for azacitidine maintenance in patients with

Bone Marrow Disease(s): 

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Author(s): 
Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y
Primary Author: 
Nazha A
Journal Title: 
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
Original Publication Date: 
Nov 2020

Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for

Bone Marrow Disease(s):